Early clinical trial results suggest that swine flu vaccines now being rushed through development produce a strong immune response, suggesting they should work well, the head of Europe's drugs watchdog said today.

"It seems to be quite promising," Thomas Lonngren, executive director of the European Medicines Agency (EMEA), told reporters.

"The immune respomnse to all these vaccines is a very high response, whatever type of vaccine it is, whether it is adjuvanted or non-adjuvanted," he added.

Adjuvants are substances added to vaccines to boost their effectiveness.

The EMEA's expert committee on new medicines will consider the first three H1N1 swine flu vaccines from GlaxoSmithKline, Novartis and Baxter at its next meeting during the week commencing Sept. 21.

If all goes well, the first swine flu vaccines could be licensed by the European Commission early in October, Lonngren said.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.